A Phase 3 Randomized, Double-blind, Active-controlled, Multicenter Study Of The Long-term Safety And Efficacy Of Subcutaneous Administration Of Tanezumab In Japanese Adult Subjects With Chronic Low Back Pain

Trial Profile

A Phase 3 Randomized, Double-blind, Active-controlled, Multicenter Study Of The Long-term Safety And Efficacy Of Subcutaneous Administration Of Tanezumab In Japanese Adult Subjects With Chronic Low Back Pain

Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs Tanezumab (Primary) ; Celecoxib
  • Indications Back pain
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms TANGO
  • Sponsors Pfizer
  • Most Recent Events

    • 13 Jun 2017 According to a Pfizer media release, results from this study are expected in 2018.
    • 18 Jan 2017 Planned End Date changed from 1 Jul 2018 to 1 Jun 2019.
    • 18 Jan 2017 Planned primary completion date changed from 1 Jul 2018 to 1 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top